uploads/2018/12/PFE-con-1.png

Pfizer and GlaxoSmithKline’s Consumer Health Business

By

Updated

Pfizer’s business

Pfizer’s (PFE) consumer health business generated revenues of $2.6 billion during the first nine months in 2018—compared to $2.5 billion during the same period in 2017, which reflects ~4% YoY (year-over-year) growth.

In the US market, Pfizer’s consumer health business’ net revenues during the first nine months of 2018 were $1.4 billion—compared to the first nine months of 2017, which reflects ~1% YoY growth. In international markets, Pfizer’s consumer health business’ net revenues during the first nine months of 2018 were to $1.27 billion—compared to $1.18 billion during the same period in 2017, which reflects ~8% YoY growth.

In the third quarter, Pfizer’s consumer health business reported revenues of $839.0 million—compared to $829.0 million in the third quarter of 2017, which represents ~1% YoY growth.

In the US and international markets, Pfizer’s consumer health segment generated revenues of $445.0 million and $394.0 million, respectively, which reflects an ~1% YoY decline and $4% YoY growth.

Article continues below advertisement

GlaxoSmithKline’s business

In the third quarter, GlaxoSmithKline’s (GSK) consumer health business reported revenues of 1.9 billion British pounds, which reflects 1% AER (annual equivalent rate) decline and 3% CER (constant exchange rate) growth.

GlaxoSmithKline’s consumer health business’ net revenues during the first nine months were 5.8 billion British pounds, which reflects ~2% AER decline and ~2% CER growth. GlaxoSmithKline’s oral health pushed the revenue growth, which was partially offset by a decline in Panadol sales.

In GlaxoSmithKline’s consumer health business, wellness, oral health, nutrition, and skin health generated revenues of 2.9 billion British pounds, 1.9 billion British pounds, 489.0 million British pounds, and 453.0 million British pounds, respectively, in the first nine months of 2018.

In the United States, Europe, and international markets, GlaxoSmithKline’s consumer health business generated revenues of 1.3 billion British pounds, 1.8 billion British pounds, and 2.6 billion British pounds, respectively.

Next, we’ll discuss what investors can expect from Pfizer and GlaxoSmithKline’s consumer health joint venture.

Advertisement

More From Market Realist